erythrocyte membrane protein band 4.2Genealiases: PA · SPH5
Q-omics provides the consensus-scored EPB42 profile across patient tissues and cancer cell-line models. EPB42 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, EPB42 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, EPB42 protein abundance shows 17,720 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight SCLC, LUSC, and CCRCC as cancer lineages where EPB42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPB42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPB42 survival associations across molecular data types. EPB42 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPB42 RNA expression–survival associations across cancer types. High EPB42 expression shows unfavorable associations in SCLC, STAD, KICH, OV and UVM, but favorable associations in LUAD. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for EPB42 RNA expression.
This table summarizes EPB42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 7. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EPB42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPB42 shows lower tumor expression in LUSC, BRCA, LUAD, KICH and UCEC and higher tumor expression in CHOL. The LUSC box plot shows higher EPB42 RNA expression in normal versus tumor tissue (log2 FC = −0.139, t-test p < 0.001).
This table shows molecular features associated with EPB42 in patient tissues and cancer cell lines. In patient samples, EPB42 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, EPB42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
